本文转载自会会药咖全球顶级制药公司瑞士罗氏悄悄签下两份重要的中国协议。2025年初,罗氏与信达生物达成一项价值10.8亿美元的交易,获得一款靶向DLL3的抗体药物偶联物(ADC);10月,罗氏再次与出手翰森制药签订协议,以14.5亿美元获取一款靶向CDH17的ADC药物。这并非罗氏在中国的独舞,而是众多跨国药企竞相与中国生物科技公司合作的缩影。一笔总额可能达到114亿美元的交易也在业内引起了轰动。...
Source Link本文转载自会会药咖全球顶级制药公司瑞士罗氏悄悄签下两份重要的中国协议。2025年初,罗氏与信达生物达成一项价值10.8亿美元的交易,获得一款靶向DLL3的抗体药物偶联物(ADC);10月,罗氏再次与出手翰森制药签订协议,以14.5亿美元获取一款靶向CDH17的ADC药物。这并非罗氏在中国的独舞,而是众多跨国药企竞相与中国生物科技公司合作的缩影。一笔总额可能达到114亿美元的交易也在业内引起了轰动。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.